Section Arrow
Quote
JAZZ.NASDAQ
- Jazz Pharmaceuticals plc
Quotes are at least 15-min delayed:2026/08/31 16:46 EDT
After Hours
Last
 250.68
0 (0.00%)
Bid
240
Ask
269
High 250.7051 
Low 250.63488 
Volume 190.91K 
Regular Hours (Closed)
Last
 250.68
+6.14 (+2.51%)
Day High 
252.715 
Prev. Close
244.54 
1-M High
266.375 
Volume 
1.22M 
Bid
240
Ask
269
Day Low
241.39 
Open
241.39 
1-M Low
240.631 
Market Cap 
15.87B 
Currency 美元 
P/E 16.74 
%Yield -- 
10-SMA 251.62 
20-SMA 252.42 
50-SMA 246.93 
52-W High 266.375 
52-W Low 123.88 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
14.61/20.63
Enterprise Value
20.25B
Balance Sheet
Book Value Per Share
73.97
Cash Flow
Cash Flow Yield
0.11
Income Statement
Total Revenue
4.27B
Operating Revenue Per Share
58.45
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CLGNCollPlant Biotechnologies Ltd0.3879+0.0299+8.35%-- 
After Hours 0.3631 -0.0248 -6.39%
AIMAIM ImmunoTech Inc.0.226-0.0324-12.54%-- 
After Hours 0.2451 +0.0191 +8.45%
ROIVRoivant Sciences Ltd34.64-0.07-0.20%-- 
After Hours 34.45 -0.19 -0.55%
CVKDCadrenal Therapeutics Inc1.75+0.21+13.64%-- 
After Hours 1.69 -0.06 -3.43%
MRNAModerna140.34+2.35+1.70%-- 
After Hours 139.4 -0.94 -0.67%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.